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ABSTRACT

ARTICLE HISTORY

Protective T cell responses against tumors require the production of Interferon gamma (IFN-γ). However,
tumor-infiltrating T cells (TILs) gradually lose their capacity to produce IFN-γ and therefore fail to clear
malignant cells. Dissecting the underlying mechanisms that block cytokine production is thus key for
improving T cell products. Here we show that although TILs express substantial levels of Ifng mRNA,
post-transcriptional mechanisms impede the production of IFN-γ protein due to loss of mRNA stability.
CD28 triggering, but not PD1 blocking antibodies, effectively restores the stability of Ifng mRNA.
Intriguingly, TILs devoid of AU-rich elements within the 3ʹuntranslated region maintain stabilized Ifng
mRNA and produce more IFN-γ protein than wild-type TILs. This sustained IFN-γ production translates
into effective suppression of tumor outgrowth, which is almost exclusively mediated by direct effects on
the tumor cells. We therefore conclude that post-transcriptional mechanisms could be modulated to
potentiate effective T cell therapies in cancer.

Received 20 June 2018
Revised 20 September 2018
Accepted 26 September 2018

Introduction
+

Cytotoxic CD8 T cells can be very potent in anti-tumoral
therapies. In fact, more than 50% of the patients suffering
from metastatic melanoma respond to T cell therapy with ex
vivo expanded tumor-infiltrating T cells (TILs), of which
10–20% experience complete remission1,2.
A critical feature of CD8+ T cell responses is the release of
effector molecules, and the pro-inflammatory cytokine interferon gamma (IFN-γ) is key herein. Deletion of the IFN-γ
gene, and loss of the IFN-γ receptor signaling pathway
resulted in spontaneous tumor development in mice, and
in loss of tumor suppression3,4. A high IFN-γ-mediated
gene signature has been associated with better survival for
melanoma patients5. In addition, genetic screens revealed
that modulating IFN-γ responses in tumors leads to loss of
responsiveness to immunotherapies6, which is further
emphasized by the fact that genetic variations of the interferon signaling pathway in humans correlate with cancer risk
and survival7.
A major limitation of effective anti-tumor responses by
TILs is the loss of effector function, i.e. the failure to
produce effector molecules such as IFN-γ 8–10. Several
signals can drive this loss of cytokine production, such as
chronic exposure to antigen and to inhibitory molecules,
restriction of glucose, and increase of fatty acid oxidation1116
. These events, however, do not fully explain the loss of
effector function within the tumor microenvironment.
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Recently, post-transcriptional regulatory mechanisms
have become appreciated in modulating the production of
cytokines. For instance, AU-rich elements (AREs) within
the 3ʹuntranslated region (3ʹUTR) determine the fate of
mRNAs by regulating their stability, subcellular localization, and translation17-20. We found that these regulatory
mechanisms differentially dictate the cytokine production
of T cells21. The immediate production of IFN-γ mainly
depends on rapid translation of pre-formed mRNA,
whereas prolonged cytokine production relies on de novo
transcription and increased mRNA stability21. Furthermore,
limited de novo transcription and the lack of Ifng mRNA
stabilization effectively restricts the magnitude and duration
of IFN-γ production22. Whether and how post-transcriptional regulatory mechanisms govern the production of
IFN-γ in T cells during an acute infection, and how this
compares to cytokine production during chronic antigen
exposure in tumors is not well understood.
Here, we discovered a hitherto unappreciated role of
post-transcriptional regulation that restricts the production
of IFN-γ T cells within the tumor environment.
Importantly, removing AREs from the Ifng locus was sufficient for TILs to retain the production of IFN-γ, and thus
their capacity to suppress the tumor outgrowth. We therefore propose that adoptive T cell therapy could be potentiated by relieving IFN-γ from post-transcriptional control
mechanisms.

CONTACT Monika C. Wolkers
m.wolkers@sanquin.nl
Department of Hematopoiesis, Sanquin Research-Landsteiner Laboratory, Amsterdam UMC, University
of Amsterdam, Plesmanlaan 125, Amsterdam, CX 1066, The Netherlands.
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.
U.S. government works are not subject to copyright.
Supplemental data for this article can be accessed here.
© 2018 Taylor & Francis Group, LLC

F. SALERNO ET AL.

in qualitative, but in quantitative differences in IFN-γ
production.

Results
Germ-line deletion of AREs within the Ifng 3ʹUTR
augments protein production upon T cell activation
We first investigated how the 3ʹUTR of Ifng mRNA controls
the protein production upon T cell priming. To this end, we
compared OT-I TCR transgenic T cells from wild type (WT)
mice with those of ARE-Del mice that lack the ARE region
within the Ifng 3ʹUTR23. FACS-sorted naive WT OT-I and
heterozygous ARE-Del OT-I T cells were activated for 1 day
with OVA257-264 peptide-loaded bone marrow-derived dendritic cells. We then measured the production of IFN-γ upon
incubation with brefeldin A for the last 3 h of culture, without
the addition of exogenous peptide. Both ARE-Del and WT
OT-I T cells required that dendritic cells were loaded with at
least 0.1 nM peptide to reach detectable production of IFN-γ
(Figure 1A). However, after 1 day of T cell priming ARE-Del
T cells produced markedly higher levels of IFN-γ than WT
OT-I T cells. This was detectable both in terms of the percentage of IFN-γ producing T cells and the amount of IFN-γ
produced per cell, as measured by IFN-γ mean fluorescence
intensity (Figure 1A, Fig S1A). The production of TNF-α,
however, remained equal between WT and ARE-Del T cells
(Figure 1A, Fig S1A). Interestingly, ARE-Del T cells continued
to produce greater levels of IFN-γ also after 3 days of T cell
priming (Figure 1B). Together, our data demonstrate that
germ-line loss of AREs within the Ifng 3ʹUTR does not result

We next compared the in vivo responsiveness of ARE-Del T
cells to an acute infection with that of WT T cells. We transferred 1 × 103 FACS-sorted naive WT or ARE-Del OT-I T cells
into C57BL/6J/Ly5.1 recipient mice and infected the mice the
following day with 2.5 × 104 Listeria monocytogenes expressing
Ovalbumin (LM-OVA24). T cell expansion during the course of
infection was similar between the two T cell types, as judged
from the percentage of WT and ARE-Del OT-I T cells in the
peripheral blood (Figure 1C). The ex vivo production of IFN-γ
in WT T cells from peripheral blood samples peaked 9 days
after infection, as determined by incubation with brefeldin A
for 3 h prior to analysis (Figure 1C, D). Interestingly, ARE-Del
T cells produced maximal levels of IFN-γ already at day 6 post
infection, and the mean fluorescence intensity levels of IFN-γ
per transferred ARE-Del T cells were substantially higher at all
time points measured (Figure 1C, D).
Memory T cells become rapidly activated upon secondary
infection and produce massive amounts of cytokines25,26.
Indeed, more than 80 ± 6% and 90 ± 2% of WT and AREDel memory T cells, respectively, produced IFN-γ after 6 h of
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Figure 1. Germ-line deletion of AREs within the Ifng 3ʹUTR induces superior IFN-γ production. (A) Naive CD44lowCD62Lhi WT and ARE-Del OT-I T cells were cocultured for 24 h with OVA257-264 peptide-loaded bone marrow derived dendritic cells (DCs) as indicated. For the last 3 h, 1 μg/ml brefeldin A (BrfA) was added prior
to analysis of IFN-γ (left) and TNF-α (right) production by intracellular cytokine staining. Graphs display percentage of cytokine producing T cells. (B) Representative
dot plots of IFN-γ producing WT and ARE-Del T cells at day 1 (top), and day 3 (bottom) post activation as described in (A). (C) C57BL/6J/Ly5.1 mice received 1 × 103
naive WT, or ARE-Del OT-I T cells, and were infected the next day with 2 × 104 LM-OVA. The % (left), and the IFN-γ production (right) of transferred OT-I T cells was
determined in peripheral blood samples after 3 h incubation with BrfA by flow cytometry. (D) Representative IFN-γ stainings of WT (gray histograms) and ARE-Del
(black line) T cells in peripheral blood at indicated time points. (E) Representative dot plots of mice rechallenged with 2 × 105 LM-OVA 35 days post primary infection.
6 h and 24 h post infection, the IFN-γ production of splenic T cells was measured after 3 h incubation with BrfA. [Unpaired student t-test; (A) n = 3 mice per group;
*p < 0.05. (C) n = 8 mice per group; **p < 0.005; ****p < 0.0001].
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reinfection with high dose LM-OVA (2.5 x 105; Figure 1E). At
24 h after reinfection, however, the ex vivo production of IFNγ by WT T cells dropped by half to 36 ± 20%, whereas
75 ± 10% of ARE-Del T cells retained high IFN-γ levels
(Figure 1E). Thus, whereas the antigen threshold for AREDel and WT T cells to produce cytokines is equal, ARE-Del T
cells outcompete WT T cells in the magnitude and the duration of IFN-γ production.

of TNF-α and IL-2 by WT and ARE-Del TILs was undetectable, when we measured cytokine production in tumor digests
ex vivo after 4 h of incubation with brefeldin A, without adding
exogenous peptide (Figure 2C). Also the production of IFN-γ
was limited, as only 19 ± 8% of WT TILs produced detectable
levels of IFN-γ (Figure 2D). In sharp contrast, 62 ± 10% AREDel T cells maintained high IFN-γ production levels
(Figure 2D). The superior production of IFN-γ by ARE-Del T
cells was independent of the tumor size (Fig S2D).
Furthermore, whereas spleen-derived ARE-Del and WT T
cells from tumor-bearing mice massively responded to the
addition of exogenous OVA257-264 peptide by producing IFNγ (Figure 2E, right panel) this was not the case for tumorderived OT-I T cells. We could not detect higher percentages of
IFN-γ, or higher production levels of OT-I TILs when additional antigen was provided (Figure 2E, left panel, S1E). This
finding indicates that limited antigen presentation within the
tumor tissue is not the cause of lower cytokine production by
WT OT-I T cells. Only bypassing the proximal TCR signaling
with PMA/ionomycin resulted in potent IFN-γ production of
WT TILs (Figure 2E, Fig S1E). In conclusion, AREs within the
Ifng locus promote the loss of IFN-γ production in TILs
through post-transcriptional repression.

Sustained IFN-γ production by tumor-infiltrating ARE-Del
T cells
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We next questioned whether ARE-Del T cells also responded
more vigorously to tumor cells. We co-cultured Ovalbuminexpressing B16F10 melanoma cells (B16-OVA27) for 4 h with
in vitro activated ARE-Del and WT OT-I effector T cells22.
Again, the percentage of IFN-γ – but not of TNF-α and IL-2 –
producing T cells was significantly higher in ARE-Del T cells
than in WT T cells (Figure 2A, Fig S1B).
To determine how T cells responded to established tumors
in vivo, we injected 1 × 106 WT or ARE Del OT-I effector T
cells into B16-OVA tumor-bearing mice, which had received
3 × 105 tumor cells subcutaneously 7–10 days earlier. At
14 days post T cell transfer, we could not detect any differences in the percentage of WT and ARE-Del T cell infiltrates
in the tumors (TILs; Figure 2B), suggesting that T cell proliferation and/or maintenance was unaffected by the ARE
deletion. Also the expression levels of CD44 and CD62L,
and the percentage of TILs expressing the degranulation marker CD107a were identical between WT and ARE-Del TILs
(Fig S1C, and Figure 2C).
Chronically activated T cells gradually lose their capacity to
produce effector molecules28. In line with that, the production
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Figure 2. ARE-Del T cells retain IFN-γ production within the tumor environment. WT and ARE-Del OT-I T cells were activated for 20 h with MEC.B7.SigOVA cells
and subsequently cultured with rIL-2 for 4 days. T cells were then (A) co-cultured for 4 h with indicated amounts of B16-OVA cells in the presence of BrfA, or (B-E)
injected (1 × 106 WT or ARE-Del OT-I T cells) i.v. into C57BL/6J/Ly5.1+ mice bearing B16-OVA tumors that had reached a size of ~ 8mm3. 14 days later, tumors were
excised and analyzed for (B) percentage of WT and ARE-Del OT-I TILs. (C-D) Intracellular staining for CD107a, TNF-α, IL-2 (C), and IFN-γ (D) of WT and ARE-Del OT-I
TILs was performed ex vivo after 4 h incubation with BrfA/monensin. (E) Spleen- and tumor-derived OT-I T cells were activated for 4 h with 100 nM OVA257–264
peptide or with PMA/ionomycin in the presence of BrfA, or were left untreated (-). For representative dot plots, see Fig S1E. (A-E) Data are representative or were
pooled from 3 independently performed experiments ± SD. (A) n = 4; (B-E) n = 9–12; [Unpaired student t-test; ns = non-significant; *p < 0.05, ****p < 0.0001].
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Increased IFN-γ production by ARE-Del TILs alters the
phenotype of macrophages
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IFN-γ can exert pleiotropic effects on the immune system and
on the inflamed tissue29,30. To identify the mechanisms that
ARE-Del T cells use to block the tumor outgrowth, we analyzed
the lymphoid and myeloid tumor infiltrates. The absolute numbers of live CD45+ cells was equal in tumors from mice treated
with WT or ARE-Del T cells (Figure 4A). This was also reflected
by similar percentages of CD3+ T cells, CD8+ T cells, CD4+ T
cells, regulatory T cells, NK cells, and B cells (Figure 4B).
Furthermore, the endogenous CD8+ T cell and NK cell infiltrates
had a similar potential to produce IFN-γ or to express the
degranulation marker CD107a (Fig S2A).
To determine the nature of myeloid tumor infiltrates, we
distinguished three different populations based on their forward
scatter/side scatter profile and the expression of CD11b, Ly6G/C
and F4/8031. The tumor-infiltrating CD11bhi Ly6G/Chi neutrophils were equal in tumors treated with WT and ARE-Del T
cells, both in terms of percentage and their activation status as
judged from the expression levels of CD63 and ICAM-1 (CD54)
(Figure 4C; Fig S2B). Also the percentage of migrating CD11bhi
F4/80int monocytes that represent the major source of macrophages in inflamed tissues31 did not change (Figure 4C, D). Yet,
the percentage of fully differentiated CD11bhi F4/80hi macrophages consistently increased from 7 ± 3% in mice treated with
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Figure 3. Sustained IFN-γ production by ARE-Del TILs results in superior
anti-tumor responses. (A) Tumor size and (B) survival of B16-OVA tumorbearing mice that were treated with 2 × 106 WT OT-I, or 2 × 106 ARE-Del OT-I
T cells, or left untreated (no T cells) at day 7 after tumor injection. Lack of
survival was defined as death or tumor size > 1000 mm3. Data represent 2
independently performed experiments. [n = 7 mice/group; Gehan-BreslowWilcoxon test; p < 0.0001].
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acceptable tumor size of 1000 mm3 within 20 days post tumor
injection (Figure 3A, B). As previously shown27, T cell therapy
with WT OT-I T cells significantly delayed the tumor outgrowth (Figure 3A), and it increased the 50% survival rate
from 18 days to 25 days (p = 0.0005; Figure 3B). Remarkably,
T cell transfer with ARE-Del T cells substantially extended
this therapeutic effect, increasing the 50% survival rate from
25 days to a striking 43 days when compared to T cell transfer
with WT T cells (p = 0.02; Figure 3A, B). Thus, the removal of
AREs within the Ifng 3ʹUTR suffices to significantly potentiate
the therapeutic effects of T cell therapy.
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Figure 4. ARE-Del TIL therapy promotes the pro-inflammatory profile of tumor-associated macrophages. (A) Absolute numbers of live CD45+ infiltrates in
tumors from mice that had received WT OT-I (grey) or ARE-Del OT-I (white) T cells. (B) Percentage of total CD3+ cells, CD3+CD8+OT-I− T cells (CD8+),
CD3+CD4+FoxP3− T cells (CD4+), CD3+CD4+FoxP3+ regulatory T cells (Treg), CD3−NK1.1+ cells (NK), and CD3−CD19+ B cells of the CD45+ tumor-infiltrating population.
(C-D) Percentage of CD11bhiLy6G/Chi, CD11bhiF4/80int, and CD11bhiF4/80hi cells of CD45+ population, and (D) representative dot plot of CD11bhiF4/80int and
CD11bhiF4/80hi cells. (E) MHC-I (left) and MHC-II (right) expression levels on tumor-infiltrating CD11bhiF4/80int monocytes and CD11bhiF4/80hi macrophages.
(F) CD206 expression on CD11bhiF4/80hi tumor-infiltrating macrophages. Data were pooled from 3 independently performed experiments ± SD. [(A-E) n = 12; (G)
n = 6–9 mice/group; (C, F) Unpaired Student t-test; (E) One-way ANOVA with Tukey’s multiple comparison; ns = non-significant; *p < 0.05; **p < 0.005;
***p < 0.0005; ****p < 0.0001].
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and MHC-II were found on tumor cells ex vivo after treatment with WT T cells, and these markers were further
enhanced upon ARE-Del T cell therapy (Figure 5A).
We next investigated whether IFN-γ directly affected the
proliferation of tumor cells. Indeed, B16-OVA cells cultured
in vitro with rIFN-γ lost their capacity to expand (Figure 5B).
This was at least in part due to a block in proliferation as
determined with the cell trace dye CFSE (Figure 5C). As
expected, IFN-γR−/- B16-OVA cells were refractory to
rIFN-γ (Figure 5B, C). Importantly, we confirmed this block
of proliferation in vivo. The incorporation of thymidine analog bromodeoxyuridine (BrdU) revealed that the absolute
number of B16-OVA cells in S phase (BrdU+) within tumors
was lower in mice that were treated with ARE-Del T cells than
when treated with WT T cells (Figure 5D). This decline in
tumor cell proliferation directly correlated with the superior
IFN-γ production by ARE-Del TILs (Figure 5D).
We next examinated how the loss of the IFN-γ receptor on
tumor cells would affect the anti-tumoral effect of WT and
ARE-Del T cells. Again, the percentage of OT-I T cell infiltrates was equal, and ARE-Del T cells maintained their superior production of IFN-γ, whether the tumors expressed
IFN-γR or not (Fig S2E). However, the therapeutic advantage

WT T cells to 12 ± 4% in mice that received ARE-Del T cells
(p = 0.0057; Figure 4C, D). CD11bhi F4/80hi macrophages
expressed higher MHC-I and MHC-II levels than the CD11bhi
F4/80int monocytic fraction (Figure 4E). When ARE-Del T cells
were transferred into tumor-bearing mice, the levels of MHC-II
on fully differentiated CD11bhi F4/80hi macrophages further
increased (Figure 4E). In addition, we observed reduced expression levels of the mannose receptor CD206 (Figure 4F), a marker
that is associated with the anti-inflammatory phenotype of
macrophages32. These findings thus indicate that the continuous
IFN-γ production in tumors by ARE-Del T cells augments the
numbers of tumor-associated macrophages with a pro-inflammatory phenotype.
Continuous IFN-γ production by ARE-Del T cells directly
affects the tumor outgrowth
IFN-γ can also directly act on tumor cells30. Indeed, treating
B16-OVA melanoma cells in vitro with recombinant IFN-γ
(rIFN-γ) increased the expression levels of PD-L1, MHC-I
and MHC-II, which was completely lost when the IFN-γ
receptor 1 was deleted by CRISPR/Cas9 (IFN-γR−/-) (Fig
S2C, D). Similarly, high expression levels of PD-L1, MHC-I
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Figure 5. ARE-Del T cell therapy directly alters the tumor cell phenotype and growth. (A) Ex vivo PD-L1, MHC-I and MHC-II expression levels of tumor cells
isolated from tumor-bearing mice treated with WT or ARE-Del OT-I T cells. Data pooled from 4 (PD-L1 and MHC-II; n = 19) and 2 (MHC-I; n = 6–8) independently
performed experiments (mean ± SD). [Unpaired Student t-test; **p < 0.005; ***p < 0.0005]. (B-C) B16-OVA IFN-γR−/- and Cas9 control tumor cells were cultured with
or without 50IU rIFN-γ. (B) Cell were counted at indicated times (mean ± SD; n = 3). (C) B16-OVA cells were labeled with CFSE, and cell proliferation was monitored
by flow cytometry as determined by loss of CFSE expression. Representative of n = 3. (D) 8 days after WT or ARE-Del OT-I T cell transfer, tumor cell proliferation was
assessed 2.5 h after i.p. injection of BrdU in B16-OVA tumor-bearing mice. Left: Absolute numbers of BrdU+ CD45− CD4+ B16-OVA tumor cells analyzed directly ex
vivo. Right: ex vivo IFN-γ production of transferred OT-I T cells after 3 h incubation with BrfA (mean ± SD; n = 3–6 mice/group). [Unpaired Student t-test; *p < 0.05].
(E) Survival curve of mice challenged with Cas9 control or IFN-γR−/- B16-OVA cells treated with WT or ARE-Del OT-I T cells. [n = 7 and n = 6 mice per control and IFNγR−/- groups, respectively; Gehan-Breslow-Wilcoxon test]. Data represent 2 independently performed experiments.

F. SALERNO ET AL.

tumor-derived T cells compared to spleen-derived T
cells: despite the loss of IFN-γ production, WT TILs maintained higher Ifng mRNA levels than the spleen-derived
OT-I T cells (Figure 6A). Similarly, human melanomaspecific TILs completely fail to produce IFN-γ protein
upon activation9,33. Yet, we observed in previously published data sets that melanoma-specific TILs express
higher IFNG mRNA levels as compared to their peripheral
blood-derived counterparts9. Of note, ARE-Del TILs
expressed yet another 2-fold more Ifng mRNA than WT
TILs (Figure 6A), again pointing towards post-transcriptional regulation as a critical regulator in this process.

of ARE-Del T cells over WT T cells was completely abrogated
on IFN-γR−/- tumors (Figure 5E). This was not a mere effect
of loss of antigen presentation, because the basal levels of
MHC I expression was sufficient to induce the production
of IFN-γ by OT-I T cells both in vivo, and in vitro (Fig S2E,
F). In conclusion, relieving IFN-γ from post-transcriptional
regulation boosts the therapeutic potential of T cell therapy
predominately through direct effects of IFN-γ on the tumor
cells, and is at least in part due to a block in tumor cell
proliferation.
Tumor-specific TILs express more Ifng mRNA than
peripheral T cells in mouse and human

Superior IFN-γ production by ARE-Del T cells correlates
with increased mRNA stability

Our data thus far demonstrate that AREs in the Ifng
3ʹUTR regulate the loss of cytokine production in TILs.
This finding corroborated with a clear discrepancy
between Ifng mRNA levels and IFN-γ protein levels in
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experiments (mean ± SD; n = 9 mice/group). [One-way ANOVA with Tukey’s multiple comparison; *p < 0.05; ****p < 0.0001]. (B-E) WT and ARE-Del OT-I T cells were
co-cultured with B16-OVA (B-C) or MC38-OVA (D-E) cells at a 6:1 effector:target (E:T) ratio for indicated time. B16-OVA or MC38-OVA cells were refreshed daily. (B, D)
Intracellular IFN-γ and TNF-α staining was performed at day 1 to 3 after adding BrfA during the last 2 h of culture. (C, E) Ifng mRNA expression was analyzed by RTPCR. Representative dot plots (B) and pooled data ± SD (C-E) from 4 (B-C) and 2 (D-E) independently performed experiments. [Unpaired Student t-test; *p < 0.05;
**p < 0.005]. (F-G) Ifng mRNA decay of resting T cells, and of T cells co-cultured in vitro with B16-OVA or MC38-OVA cells for 1 or 3 days (F), or Ifng mRNA decay of in
vivo tumor derived WT and ARE-Del TILs (G) measured by adding 1 μg/ml ActD for indicated time points. Presented data are pooled from 4 (n = 5; F) and 2 (n = 5; G)
independently performed experiments (mean ± SD). [Unpaired Student t-test; *p < 0.05; **p < 0.005; ***p < 0.0005].
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culture system with tumor cells. When antigen-experienced T
cells were exposed to B16-OVA tumor cells for 1 day, both
WT and ARE-Del OT-I T cells potently produced IFN-γ, as
defined by adding Brefeldin A for the last 2h of co-culture
(Figure 6B). However, re-exposure to freshly seeded B16OVA cells for a second time showed a substantial reduction
of the IFN-γ production of WT T cells (from 75 ± 13% to
51 ± 6%), and this response was almost completely lost after a
third exposure to B16-OVA cells (9 ± 6%; Figure 6B). AREDel T cells, however, maintained their responsiveness to
tumor cells for an extended period, with 57 ± 15% of the T
cells producing IFN-γ at day 3 (Figure 6B).
Intriguingly, irrespective of the loss of cytokine production
in WT T cells, the Ifng mRNA levels of WT and ARE-DEL T
cells were indistinguishable at day 1 and 2 of co-culture with
B16-OVA cells (Figure 6C). At day 3, however, ARE-Del T
cells maintained significantly higher levels of Ifng mRNA
compared to WT T cells (Figure 6C). Similar results were
obtained when WT and ARE-Del T cells were exposed to
murine colon adenocarcinoma-derived MC38-OVA cells
(Figure 6D, Fig S3A). Also in this tumor model, ARE-Del T
cells produced significantly more IFN-γ than WT T cells
(Figure 6D, Fig S3A). Yet differences of Ifng mRNA levels
between WT and ARE-Del T cells were only observed at day
3after continuous exposure to tumor cells, and not upon 1 day
of co-culture (Figure 6E).
We next determined whether differences in mRNA stability resulted in the dissimilar Ifng mRNA levels between WT
and ARE-Del T cells. Non-activated WT T cells have a t1/
2 = ~ 30 min, as determined by blocking de novo transcription with Actinomycin D (Figure 6F; ref22). When T cells
were cultured with B16-OVA or with MC38-OVA cells for
1 day, the Ifng mRNA stability substantially increased to t1/
2 > 2 h (Figure 6F). However, after 3 days of co-culture, the
t1/2 dropped back to ~ 1 h (Figure 6F). In sharp contrast,
ARE-Del T cells maintained stable Ifng mRNA throughout
the entire co-culture (t1/2 > 2 h; Figure 6F). This disparity of
Ifng mRNA turn-over rates was also found in FACS-sorted
TILs from B16-OVA tumor-bearing mice that displayed a t1/
2 = ~ 30 min for WT TILs as opposed to t1/2 > 1 h for AREDel TILs (Figure 6G). Together, these results demonstrate
that mRNA stabilization drives elevated Ifng mRNA levels,
which potentially promotes the superior and prolonged cytokine production by ARE-Del TILs within the tumor
environment.
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and of ARE-Del T cells (from 66 ± 7% to 79 ± 8%; p = 0.04.
Figure 7B; S3D).
Recent studies showed that PD-1 blocks T cell function
by interfering with CD28 signaling36,37. In line with that,
CD80/CD86 blockade annihilated the increased IFN-γ production of PD-1 blockade, and reduced the IFN-γ levels
back to 8 ± 4% for WT and 66 ± 13% for ARE-Del T cells
(Figure 7B; S3D). Interestingly, providing CD28 costimulation to ARE-Del T cells did not increase the IFN-γ production when compared to untreated T cells (Figure 7B,
bottom panel; p = 0.1). In sharp contrast, CD28 costimulation significantly restored the responsiveness of WT T
cells to levels that were similiar to PD-1 blockade (from
9 ± 5% to 20 ± 11%; p = 0.04; Figure 7B; S3D). Combining
PD-1 blockade with CD28 costimulation even further augmented the production of IFN-γ by WT T cells when
compared to single treatments (34 ± 15%; p = 0.03 compared to αPD-1; p = 0.006 compared to αCD28;
Figure 7B; S3C).
Because both CD28 stimulation and PD-1 blockade effectively increased the IFN-γ production in WT T cells, but
only PD-1 blockade acted on ARE-Del T cells, it suggested
to us that these two pathways may employ different mechanisms. We therefore determined the effect of PD-1 blockade
and/or CD28 costimulation on the stability of Ifng mRNA.
As expected, irrespective of the antibody treatment, the Ifng
mRNA in ARE-Del T cells was always stabilized (Fig S3E).
However, despite significant increases in the IFN-γ protein
production, PD-1 blockade in WT T cells did not increase
the Ifng mRNA levels (Fig S3F), or its stability (Figure 7C).
mRNA levels and stability were identical between PD-1
blockade alone or in combination with αCD80/86
(Figure 7C, S3F). In sharp contrast, CD28 costimulation
effectively stabilized Ifng mRNA in WT T (Figure 7C). PD1 blockade could further potentiate the Ifng mRNA stabilization when combined with CD28 costimulation, which was
also concomitant with increased Ifng mRNA levels
(Figure 7C, S3F). Combined, whereas CD28 signaling and
PD-1 blockade primarily govern IFN-γ production through
different pathways, they collaborate in restoring the production of IFN-γ in tumor-exposed T cells.
Altogether, our study reveals that post-transcriptional regulation blocks the production of IFN-γ in TILs, and that loss
of this regulatory mechanism could greatly improve the therapeutic effect of T cell therapy.

Discussion
CD28 costimulation but not PD-1 blockade restores IFN-γ
production through mRNA stabilization
We next sought to identify signals that promote the stabilization of Ifng mRNA in T cells. Programmed death 1 (PD-1) and
Lymphocyte-activation gene 3 (Lag-3) are two exhaustion markers that are highly expressed on tumor-infiltrating T cells
(Figure 7A, Fig S3B, C). Blocking PD-1 can effectively reinvigorate T cell responses against tumors34,35. Indeed, co-culturing
T cells for 3 days with B16-OVA tumors in combination with
αPD-1 blocking antibody significantly increased the production
of IFN-γ of WT T cells (from 9 ± 5% to 24 ± 13%; p = 0.03),

The production of IFN-γ by TILs is critical for effective antitumoral responses. Chronic antigen exposure and immunosuppressive signals within the tumor environment, however,
impede the effector function of TILs. Here, we show that the
loss of IFN-γ production is linked to rapid Ifng mRNA decay
that is mediated by AREs located within its 3ʹUTR.
Despite the epigenetic changes that arise early during T cell
activation38-40, tumor-specific TILs maintain higher levels of
Ifng mRNA. As human melanoma-specific TILs alike9, TILs
isolated from B16-OVA tumors expressed higher levels of Ifng
mRNA than blood- or spleen-derived T cells of the same
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antigen specificity (Figure 6). Yet, TILs fail to translate the
mRNA into protein9,33. Even though nutritional and metabolic restrictions within the tumor environment can block
protein production14-16, we show here that the mere removal
of ARE sequences from the Ifng 3ʹUTR is sufficient to bypass
this inhibitory state. Thus, mRNA stabilization contributes to
ensure effective IFN-γ production by TILs.
Which signals interfere with the stability of Ifng mRNA in
TILs is yet to be determined. We previously showed that PKC
signaling is critical for the stabilization of Ifng mRNA in activated
T cells21. PKC can regulate the activity of RNA-binding proteins
that drive mRNA stabilization in cell lines41,42. CD28 costimulation, which can enhance cytokine mRNA stability (ref43 and
Salerno, Freen-van Heeren et al., bioRxiv 375840), also amplifies
PKCθ signaling in T cells44,45 and activate stabilizing RNA-binding proteins46. In line with that, CD28 costimulatory signals in
tumor-exposed T cells effectively stabilized Ifng mRNA and
restored IFN-γ protein production. This may occur by controlling the function of ARE-binding proteins through PKC.
The recovery of protein production upon PD-1 blockade
was similar to that of CD28 costimulation. However, in line
with recent studies that found no changes in Ifng mRNA
levels and/or epigenetic signature upon PD-1 blockade38,
this treatment also failed to stabilize Ifng mRNA in dysfunctional T cells (Figure 7). These findings were unexpected

because PD-1 signaling recruits SHP-1/2 and dephosphorylates Zap70, which in turn inactivates PKC signaling47.
Interestingly, PD-1 signaling recruits SHP2 also to CD28
and thus blocks T cell function by inactivating CD28
signaling36. The efficacy of anti PD-1 therapy may therefore
depend on the levels of actual CD28 signaling37. That CD28
signaling stabilizes Ifng mRNA while PD-1 blockade fails to
do so could therefore result from different signal strengths
from these two antibody treatments. Alternatively, PD-1
blockade may also act on signaling pathways other than
those involved in mRNA stabilization, which may or may
not become engaged by CD28 costimulation. Because
mRNA levels and stability do not change upon PD-1 blockade, but the IFN-γ protein production resembles that of CD28
costimulation, it is tempting to speculate that the observed
IFN-γ protein production upon PD-1 blockade is mediated
through increased translation efficiency. How the translational block is regulated in TILs is yet to be determined. We
recently showed that the RNA-binding protein ZFP36L2
blocks translation of Ifng mRNA in memory T cells by interacting with the ARE region48. It is therefore conceivable that
similar mechanisms are at play in TILs.
IFN-γ is a critical factor for anti-tumoral responses3-7. Yet,
continuous IFN-γ production within the tumor can also
induce tumor escape mechanisms49,50. This effect can become
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detrimental when check point blockade is used to boost the
endogenous immune response49. However, our study indicates that the superior IFN-γ production by depleting AREs
from the 3ʹUTR may be particularly effective when effector T
cells are used for therapeutic purposes. This could boost the
efficacy of e.g. TIL therapy, TCR gene therapy or CAR-T cell
therapy.
In conclusion, post-transcriptional regulatory mechanisms
impede the production of IFN-γ by TILs. Interfering with the
turn-over rate of Ifng mRNA, e.g. by genetically altering the ciselements on the mRNA to interfere with post-transcriptional
regulation, could significantly potentiate the efficacy of T cell
therapy against tumors.

MIT, Boston), and the Ifngr1-targeting gRNA, or the empty
Cas9 vector alone was transfected into B16-OVA cells by
CaPO4 transfection. GFP-expressing cells were single-cell
sorted (BD FACSAria III Cell Sorter), and the Ifngr1 knockout
clones was identified by Sanger sequencing (forward:
5ʹCTTGCGGACTTGGCGACTAGTCTG3ʹ, reverse: 5ʹCTGC
CGTGGAAACTAACTGTAAAA3ʹ). The loss of Ifngr1 was
validated by the loss of upregulation of the IFN-γ responsive
genes PDL-1, MHC-I and MHC-II upon overnight exposure
with 50 IU/ml recombinant murine IFN-γ (rIFN-γ,
PeproTech). The proliferative capacity of IFN-γR−/- B16OVA, and Cas9 control cells was determined by cell count
and by 12.5 nM CSFE labeling over 3 days of culture.

Material and methods

B16 melanoma tumor model

Mice and cell culture

For in vivo studies, mice were injected subcutaneously with
3 × 105 B16-OVA cells, or with 3 × 106 Cas9 control or IFNγR−/- B16-OVA cells. When the tumors reached ~ 8 mm3, mice
received 1–2 × 106 WT or ARE-Del CD8+ OT-I/Ly5.2 T cells i.v.
For T cell transfer into tumor bearing mice, CD8+ T cells
were purified from spleens and lymph nodes of WT and AREDel OT-I mice by MACS selection (Miltenyi CD8 isolation
kit; 95–99% purity). T cells were activated as previously
described22. T cells were harvested, removed from the stimuli
and put to rest for 4 days at a density of 0.5 x 106/ml with
120IU/ml recombinant interleukin 2 (rIL-2; Proleukin). Prior
to T cell transfer dead cells were removed with Lympholyte M
gradient (Cedarlane).
Tumor infiltrates were analyzed 14 days after T cells transfer. For in vivo BrdU incorporation experiments, tumor cell
proliferation was studied 8 days after T cell transfer. Tumorbearing mice received 2 mg BrdU i.p. 2.5 h prior to tumor
harvest. For tumor growth studies, mice were sacrificed when
the tumor enriched a size of ~ 1000 mm3. Excised tumors
were cut into small pieces and digested with 100 μg/ml DNase
I (Roche) and 200 U/ml Collagenase (Worthington) at 37°C
for 30 min. Cells were counted, and when possible lymphocytes were enriched on a Lympholyte M gradient (Cedarlane).
T cells were incubated with 1 μg/ml brefeldin A alone for 4 h
or, when indicated, they were stimulated for 4 h with 100 nM
OVA257–264 peptide or with 10 ng/ml PMA and 1 µM ionomycin (both Sigma-Aldrich).
For in vitro studies, WT and ARE-Del OT-I T cells were
activated for 20 h with MEC.B7.SigOVA cells, cultured for
4 days with rIL-2 in the absence of antigen, and then reactivated by co-culture with pre-seeded B16-OVA or MC38-OVA
cells for 1 to 3 days. B16-OVA or MC38-OVA cells were
refreshed daily at a 6:1 effector:target ratio. When indicated,
T cells were daily treated with 10 μg/ml of the following
purified antibodies: anti-mouse CD28 (PV-1; Bioceros), antimouse CD279 (PD-1; 29F.1A12), anti-mouse CD80 (1610A1), and anti-mouse CD86 (GL-1; all eBioscience).

C57BL/6J/Ly5.1 mice, C57BL/6J.OT-I (OT-I) and C57BL/6J.
OT-I ARE-Del transgenic mice (ARE-Del) were bred and
housed in the animal department of the Netherlands Cancer
Institute (NKI). All animal experiments were performed in
accordance with institutional and national guidelines and
approved by the Experimental Animal Committee of the
NKI. B16-OVA cells27 are tested negative for mycoplasma
for > 5 years and retested every 3 months. MC38-OVA cells
were kindly provided by M.Herbert-Fransen, Leiden
University, and were also tested negative for mycoplasma.
Cells were cultured in IMDM (GIBCO-BRL) supplemented with 8% FCS, 15 μM 2-mercaptoethanol, 2 mM
L-Glutamine, 20 U/mL penicillin G sodium, and 20 μg/mL
streptomycin sulfate.
In vitro T cell activation and listeria monocytogenes-OVA
infection
FACS-sorted naive CD8+CD44loCD62Lhi T cells from WT or
ARE-Del OT-I splenocytes were co-cultured for 1 or 3 days
with bone marrow-derived DCs loaded with indicated
amounts of OVA257–264 peptide as previously described21.
For infections, 1 × 103 naive WT or ARE-Del OT-I (Ly5.2)
T cells were adoptively transferred into C57BL/6J/Ly5.1 recipient mice. The next day, mice were infected i.v. with
2.5 × 104 CFU Listeria monocytogenes strain expressing
Ovalbumin (LM-OVA). For reinfections, mice received
2.5 × 105 CFU of LM-OVA 35 days upon a first infection.
6 h and 24 h later, peripheral blood and spleens were collected, and single cell suspensions were incubated with
1 μg/ml brefeldin A for 3 h before proceeding with FACS
staining.
Generation and analysis of B16-OVA IFN-γR−/- cells
IFN-γR−/- B16-OVA cells were generated using CRISPR-Cas9
and guide RNA targeting the first exon of Ifngr1: forward
5ʹTGGAGCTTTGACGAGCACTG3ʹ, reverse 5ʹCAGTGCTC
GTCAAAGCTCCA 3ʹ, as predicted with the CRISPR design
tool (http://crispr.mit.edu/). Guide RNA was subcloned into
the PX458 vector (Addgene #48138; kind gift from F. Zang,

Flow cytometry
T cells were washed with FACS buffer (phosphate-buffered
saline [PBS], containing 1% FCS and 2 mM EDTA) and labeled
for 20 min at 4°C with the following monoclonal antibodies (all
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from eBioscience): anti-CD45.1 (A20), anti-CD45.2 (104), antiCD3 (17A2), anti-CD8 (53–6.7), anti-CD4 (GK1.5), anti-FoxP3
(FJK-16s), anti-CD44 (IM7), anti-CD62L (MEL-14),
anti-CD107a (eBio1D4B), anti-PD-1 (J43), anti-Lag-3
(eBioC9B7W), anti-NK1.1 (PK136), anti-CD19 (eBio1D3),
anti-CD11b (M1/70), anti-LyG6 (RB6-8C5), anti-F4/80 (BM8),
anti-CD54 (3E2), anti-CD63 (NVG-2), anti-MHC I (H-2Kb)
(AF6-88.5.5.3), anti-MHC II (I-A/I-E) (M5/114.15.2), antiPDL1 (MIH5), anti-IFN-γ (XMG1.2), anti-TNF-α (MP6XT22), anti-IL2 (JES6-5H4). Near-IR (Life Technology) was
added to the cells to exclude dead cells from analysis. For
intracellular cytokine staining, cells were fixed and permeabilized with the cytofix/cytoperm kit (BD Biosciences). FoxP3
expression was determined upon fixation and permeabilization
with the Foxp3/Transcription Factor Staining Buffer Set
(eBioscience). BrdU staining was performed using the FITC
BrdU Flow Kit according to the manufacturer’s protocol (BD
Biosciences). When necessary, cells were incubated with antiCD16/CD32 blocking antibody (2.4 G2; kind gift from Louis
Boon, Bioceros). Flow cytometry analysis was performed on
LSR-II and LSR Fortessa (BD Biosciences). Data were analyzed
with FlowJo software (Tree Star, version 10).
Quantitative PCR analysis
Total RNA was extracted using Trizol reagent (Invitrogen).
cDNA was synthesized using SuperScript III Reverse
Transcriptase (Invitrogen). Quantitative Real-Time PCR was
performed with SYBR green, a StepOne Plus RT-PCR system
(both Applied Biosystems), and with previously described
primers22. Reactions were performed in triplicate. Ct values
were normalized to L32 levels.
mRNA decay was determined upon treatment with 1 μg/ml
Actinomycin D (Sigma-Aldrich) for indicated time points.
mRNA analysis of in vivo generated TILs was performed
upon FACS-sorting of OT-I TILs based on the expression of
congenic markers CD45.1 and CD45.2.
Statistical analysis
Results are expressed as mean ± SD. Statistical analysis
between groups was performed with GraphPad Prism 6,
using unpaired Student t test when comparing 2 groups, or
1-way ANOVA test with Tukey’s multiple comparison when
comparing > 2 groups. Survival curve comparison was performed with a Gehan-Breslow-Wilcoxon test. P values < 0.05
were considered to be statistically significant.
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